Lungpacer therapy strengthened the diaphragm 246% more. Credit: Lungpacer Medical.

Lungpacer Medical is set to accelerate the RESCUE 3 pivotal clinical study with the introduction of the AeroPace System.

The AeroPace System stimulates the nerves that activate the diaphragm by providing repetitive exercises to rebuild muscle strength and enable independent, natural breathing.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The RESCUE 3 clinical study is using the minimally invasive diaphragm strengthening technology developed by Lungpacer to examine faster ventilator independence.

It will evaluate the device’s safety and efficacy, which will assist in seeking approvals from the US Food and Drug Administration (FDA) and other international regulators.

According to an abstract presented at the 2021 American College of Chest Physicians Annual Conference, Covid-19 patients treated with Lungpacer therapy showed earlier liberation compared to mechanical ventilation.

See Also:

The therapy was also demonstrated to strengthen the diaphragm 246% more, with 128% more improvement observed in lung function, according to findings from a previous Lungpacer clinical study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lungpacer CEO Doug Evans said: “The emerging research profile of AeroPace underscores the clinical potential of this therapy to play a meaningful role to limit the negative impacts of mechanical ventilation and restore strength for patients to achieve ventilator independence.

“Once approved, the AeroPace System has the potential to dramatically improve the standard of care and transform the future of ventilation.”

The company stated that the system works as a personal trainer for the diaphragm muscle.

The device offers an easy setup for patient therapy, as well as electrocardiogram (ECG)-guided catheter placement that helps to streamline clinical workload.

At present, more than 40 medical centres in France, Germany, Spain and the US are taking part in the Lungpacer therapy pivotal trial.